Redeye sees a strong positive reaction in the cards for Biovica from today’s news (after the close) regarding completed clinical validation for DiviTum, as well as a directed issue of SEK 110m through an accelerated bookbuilding process, with the caveat that the full terms of the issue are not announced at the time of writing.